Robert Nelsen - Jun 8, 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Signature
/s/ Charles Newton, as Attorney-in-fact
Stock symbol
LYEL
Transactions as of
Jun 8, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 04:18 PM
Previous filing
Jun 8, 2022
Next filing
Jul 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LYEL Common Stock 18.2M Jun 8, 2022 ARCH Venture Fund IX, L.P. F1
holding LYEL Common Stock 18.2M Jun 8, 2022 ARCH Venture Fund IX Overage, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +65K $0.00 65K Jun 8, 2022 Common Stock 65K $5.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are directly held by ARCH Venture Fund IX, L.P. ("AVF IX") (the "AVF IX Shares"). ARCH Venture Partners IX, L.P. ("AVP IX LP"), as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares. ARCH Venture Partners IX, LLC ("AVP IX LLC"), as the sole general partner of AVP IX LP, may be deemed to beneficially own the AVF IX Shares. As a managing director of AVP IX LLC, the Reporting Person may also be deemed to share the power to direct the disposition and vote of the AVF IX Shares. AVP IX LP, AVP IX LLC and the Reporting Person each disclaim beneficial ownership of the AVF IX Shares except to the extent of any pecuniary interest therein.
F2 These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("AVF IX Overage") (the "AVF IX Overage Shares"). ARCH Venture Partners IX Overage, L.P. ("AVP IX Overage LP"), as the sole general partner of ARCH IX Overage, may be deemed to beneficially own the AVF IX Overage Shares. AVP IX LLC, as the sole general partner of AVP IX Overage LP, may be deemed to beneficially own the AVF IX Overage Shares. As a managing director of AVP IX LLC, the Reporting Person may also be deemed to share the power to direct the disposition and vote of the AVF IX Overage Shares. AVP IX Overage LP, AVP IX LLC and the Reporting Person each disclaim beneficial ownership of the AVF Overage Shares except to the extent of any pecuniary interest therein.
F3 The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date.